Trials / Completed
CompletedNCT03713190
Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).
A Phase II,Randomized,Cross-over,Double-blind, Placebo- Controlled,Single Center Study of the Effect of Empagliflozin a SGLT-2 Inhibitor,on Endogenous Glucose Production and Plasma Glucagon Levels in Patients With ESRD
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- University of Pisa · Academic / Other
- Sex
- All
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
A study of the effects of empagliflozin, a SGLT-2 inhibitor, on endogenous glucose production and plasma glucagon levels in patients with end-stage renal disease (ESRD)
Detailed description
The impact of SGLT-2 inhibition on endogenous glucose production and plasma glucagon levels will be compared measured in patients with ESRD.The secondary endpoints are the mean difference in plasma glucose, insulin, c-peptide, FFA,GH, epinephrine, norepinephrine, cortisol and blood pressure during the last hour of the experiment between empagliflozin versus placebo administration in patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | Empagliflozin | Sodium-glucose co-transporter 2 (SGLT2), a low-affinity, high-capacity member of an increasingly numerous family of co-transporters, is highly expressed in the proximal renal tubule, and account for the majority of the reabsorption of filtered glucose. |
| DRUG | Placebo | A substance without specific pharmacology principles |
Timeline
- Start date
- 2018-09-10
- Primary completion
- 2020-02-15
- Completion
- 2020-03-15
- First posted
- 2018-10-19
- Last updated
- 2021-09-14
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT03713190. Inclusion in this directory is not an endorsement.